Patents Assigned to Ablynx N.V.
  • Patent number: 10273305
    Abstract: The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 30, 2019
    Assignee: Ablynx N.V.
    Inventors: Hugo Soares, Dominique Schols, Peter Vanlandschoot, Philippe Van Rompaey, Catelijne Stortelers
  • Publication number: 20190119392
    Abstract: Methods are provided for the treatment of IL-6R related diseases. More specifically, specific dose regimens and pre-filled syringes are provided for subcutaneous administration, to subjects suffering an IL-6R related disease, of immunoglobulin single variable domains that bind IL-6R.
    Type: Application
    Filed: September 27, 2018
    Publication date: April 25, 2019
    Applicant: Ablynx N.V.
    Inventors: Sven Hoefman, Maria-Laura Sargentini-Maier, Katrien Van Beneden
  • Publication number: 20190119393
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Application
    Filed: October 2, 2018
    Publication date: April 25, 2019
    Applicant: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
  • Publication number: 20190112392
    Abstract: T cell recruiting polypeptides are provided that bind the constant domain of TCR on a T cell. The polypeptides can be used in methods for treatment of cancers.
    Type: Application
    Filed: May 13, 2016
    Publication date: April 18, 2019
    Applicant: Ablynx N.V.
    Inventors: Annelies Roobrouck, Diane Van Hoorick, João Vieira
  • Publication number: 20190112363
    Abstract: The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.
    Type: Application
    Filed: September 26, 2018
    Publication date: April 18, 2019
    Applicant: Ablynx N.V.
    Inventor: Karen Silence
  • Publication number: 20190100599
    Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.
    Type: Application
    Filed: February 5, 2016
    Publication date: April 4, 2019
    Applicant: Ablynx N.V.
    Inventors: Carlo Boutton, Daniel Janssen, Peter Casteels, Peter Schotte, Francis Descamps
  • Publication number: 20190077847
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: October 17, 2017
    Publication date: March 14, 2019
    Applicant: Ablynx N.V.
    Inventors: Catelijne Stortelers, Peter Vanlandschoot, Erik Depla, Jose Melero
  • Patent number: 10214588
    Abstract: The present invention relates to methods and techniques for providing improved amino acid sequences that can be used as single antigen-binding domains. In particular, the invention relates to methods and techniques for providing improved amino acid sequences that can be used as single antigen-binding domains that comprise or essentially consist of at least one immunoglobulin sequence. More in particular, the amino acid sequences provided herein may comprise or essentially consist of at least one variable domain sequence or a suitable fragment thereof such as at least one light chain variable domain sequence (e.g. a VL-sequence) or a suitable fragment thereof or at least one heavy chain variable domain sequence (e.g. a VH-sequence or VHH sequence) or a suitable fragment thereof.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: February 26, 2019
    Assignee: Ablynx N.V.
    Inventor: Joost Alexander Kolkman
  • Publication number: 20190055322
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Application
    Filed: July 17, 2018
    Publication date: February 21, 2019
    Applicant: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • Patent number: 10208115
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: February 19, 2019
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Publication number: 20190010249
    Abstract: The present invention relates to stable formulations of polypeptides, e.g. immunoglobulin single variable domains, in particular immunoglobulin single variable domains directed against von Willebrand Factor (vWF). The invention provides formulations which are stable upon storage for prolonged periods of time and over a broad range of temperatures. The formulations of the invention ensure a high stability of the polypeptide, allowing multiple freeze-thaw cycles without chemical or physical deterioration, and provide stability in relation to mechanical stress, such as shake, shear or stir stress. They are suitable for pharmaceutical and diagnostic preparations and compatible with pharmaceutically acceptable diluents.
    Type: Application
    Filed: June 14, 2018
    Publication date: January 10, 2019
    Applicant: Ablynx N.V.
    Inventors: YVES MEYVIS, Veronique De Brabandere, Hans Ulrichts, Ann Brige, Filip Callewaert
  • Publication number: 20180362656
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Application
    Filed: October 27, 2017
    Publication date: December 20, 2018
    Applicant: Ablynx N.V
    Inventors: FRANK VERDONCK, Sigrid Cornells, Stephanie Staelens
  • Publication number: 20180362617
    Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.
    Type: Application
    Filed: May 11, 2018
    Publication date: December 20, 2018
    Applicant: Ablynx N.V.
    Inventors: ANN BRIGE, Christine Labeur, Marc Jozef Lauwereys
  • Publication number: 20180355048
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumour growth.
    Type: Application
    Filed: May 3, 2018
    Publication date: December 13, 2018
    Applicant: Ablynx N.V.
    Inventors: Francis Descamps, David Andre Baptiste Maussang-Detaille, Maarten Van Roy, Maria Gonzalez Pajuelo, Regorius Leurs, Pascal Gerard Marchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
  • Publication number: 20180355031
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to:—assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: May 10, 2018
    Publication date: December 13, 2018
    Applicant: Ablynx N.V.
    Inventors: JUDITH BAUMEISTER, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Publication number: 20180353604
    Abstract: The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.
    Type: Application
    Filed: May 3, 2018
    Publication date: December 13, 2018
    Applicant: Ablynx N.V.
    Inventors: JASON E. FERNANDEZ, Daniel A. Dixon, Andrea Paulson
  • Publication number: 20180355050
    Abstract: The present invention relates to immunoglobulins that specifically bind CD40L and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of CD40L and are safe.
    Type: Application
    Filed: November 28, 2016
    Publication date: December 13, 2018
    Applicant: Ablynx N.V.
    Inventors: Els Pattyn, Ariëlla Van de Sompel, Peter Meerts, Marie-Ange Buyse, Maarten Dewilde, Gerald Beste, Jaromir Vlach, Jonathan Hsu
  • Patent number: 10138302
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: November 27, 2018
    Assignee: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu
  • Publication number: 20180327491
    Abstract: The present invention relates to amino acid sequences and polypeptides binding to the P2X7 receptor. In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”) binding to the P2X7 receptor, as well as to proteins, polypeptides and other constructs, compounds, molecules or 5 chemical entities that comprise such ISVD's.
    Type: Application
    Filed: November 11, 2016
    Publication date: November 15, 2018
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Catelijne Stortelers
  • Patent number: 10118962
    Abstract: Processes and methods of purifying or separating Single Domain Antigen Binding (SDAB) molecules that include one or more single binding domains (e.g., one or more nanobody molecules), substantially devoid of a complementary antibody domain and an immunoglobulin constant region, using Protein A-based affinity chromatography, are disclosed.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: November 6, 2018
    Assignee: Ablynx N.V.
    Inventors: Paul R. Brown, Scott Andreas Tobler, Andrew M. Wood, Austin Wayne Boesch